This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Metadoxine is a medication used to increase the clearance of alcohol in patients with chronic alcohol dependancy.

Generic Name
Metadoxine
DrugBank Accession Number
DB16554
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 298.295
Monoisotopic: 298.116486308
Chemical Formula
C13H18N2O6
Synonyms
  • Pyridoxine mixture with Pyrrolidonecarboxylic Acid
  • Pyridoxine pyroglutamate
External IDs
  • 277-913-8

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Active Moieties
NameKindUNIICASInChI Key
PyridoxineionicKV2JZ1BI6Z65-23-6LXNHXLLTXMVWPM-UHFFFAOYSA-N
Pidolic acidionicSZB83O1W4298-79-3ODHCTXKNWHHXJC-VKHMYHEASA-N

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
EJQ7M98H5J
CAS number
74536-44-0
InChI Key
RYKKQQUKJJGFMN-HVDRVSQOSA-N
InChI
InChI=1S/C8H11NO3.C5H7NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5;7-4-2-1-3(6-4)5(8)9/h2,10-12H,3-4H2,1H3;3H,1-2H2,(H,6,7)(H,8,9)/t;3-/m.0/s1
IUPAC Name
(2S)-5-oxopyrrolidine-2-carboxylic acid; 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol
SMILES
OC(=O)[C@@H]1CCC(=O)N1.CC1=NC=C(CO)C(CO)=C1O

References

General References
  1. AIFA: Metadoxil (Metadoxine) Oral Solution, Oral Tablet, and Intramuscular and Intravenous Injection [Link]
ChemSpider
103074
Wikipedia
Metadoxine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentSevere Alcoholic Hepatitis1
4RecruitingTreatment(NAFLD) / Impaired Glucose Tolerance1
3SuspendedTreatmentNon Alcoholic Steatohepatitis (NASH)1
2CompletedTreatmentADHD - Inattentive Type2
2CompletedTreatmentAlcohol Dependency / Severe alcoholic liver disease1
2CompletedTreatmentAlcoholic Fatty Liver Disease / Alcoholic Hepatitis (AH)1
2CompletedTreatmentAttention Deficit Hyperactivity Disorder (ADHD)1
2CompletedTreatmentFragile X Syndrome (FXS)1
2, 3CompletedTreatmentAttention Deficit Hyperactivity Disorder (ADHD) / Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type1
1CompletedBasic ScienceHealthy Adult Subjects1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntramuscular; Intravenous
SolutionOral500 MG/15ML
TabletOral
TabletOral500 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-0.95ChemAxon
pKa (Strongest Acidic)9.4ChemAxon
pKa (Strongest Basic)5.58ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area73.58 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity44.11 m3·mol-1ChemAxon
Polarizability17.12 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at February 05, 2021 22:09 / Updated at May 05, 2021 20:32